bluebird bio, Inc. (BLUE): Price and Financial Metrics

bluebird bio, Inc. (BLUE)

Today's Latest Price: $51.71 USD

1.18 (-2.23%)

Updated Oct 30 4:00pm

Add BLUE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

BLUE Stock Summary

  • BLUE's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 430.72 -- higher than 92.3% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 14.29, bluebird bio Inc has a higher such ratio than 90.16% of stocks in our set.
  • Revenue growth over the past 12 months for bluebird bio Inc comes in at 323.89%, a number that bests 97.95% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to bluebird bio Inc, a group of peers worth examining would be RARE, ZYME, APTX, CLLS, and RGNX.
  • Visit BLUE's SEC page to see the company's official filings. To visit the company's web site, go to

BLUE Stock Price Chart Interactive Chart >

Price chart for BLUE

BLUE Price/Volume Stats

Current price $51.71 52-week high $99.36
Prev. close $52.89 52-week low $38.95
Day low $51.46 Volume 623,200
Day high $53.79 Avg. volume 1,022,043
50-day MA $55.80 Dividend yield N/A
200-day MA $62.00 Market Cap 3.42B

bluebird bio, Inc. (BLUE) Company Bio

Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.

BLUE Latest News Stream

Event/Time News Detail
Loading, please wait...

BLUE Latest Social Stream

Loading social stream, please wait...

View Full BLUE Social Stream

Latest BLUE News From Around the Web

Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.

EMA accepts Bluebird bio's marketing application for eli-cel gene therapy for neurodegenerative disorder

The European Medicines Agency ((EMA)) has accepted Bluebird bio's (BLUE) marketing authorization application for its investigational elivaldogene autotemcel (eli-cel, Lenti-D) gene therapy for the treatment of patients with cerebral adrenoleukodystrophy ((CALD)), a fatal neurodegenerative disease primarily affecting young boys.In July 2020, EMA's advisory group granted an accelerated assessment to eli-cel, potentially...

Seeking Alpha | October 2, 2020

bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio announces EMA's acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel gene therapy for CALD.

Business Wire | October 2, 2020

bluebird bio to Present at Jefferies Cell Therapy Virtual Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at Replays of the webcast will be available on the bluebird bio we

Business Wire | September 28, 2020

Bluebird bio’s Lentiglobin nabs PRIME status in Europe

Bluebird bio's (BLUE) LentiGlobin, an investigational gene therapy (bb1111) for the treatment of sickle cell disease ((SCD)), was granted eligibility to the Priority Medicines ((PRIME)) program by the EMA.PRIME, akin to Breakthrough Therapy status in the U.S., provides for more intensive guidance on development and accelerated review of the market application. SCD...

Seeking Alpha | September 23, 2020

bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlobin™ for SCD gene therapy (bb1111), was granted eligibility to the Priority Medicines (PRIME) program by the European Medicines Agency (EMA). The EMA’s PRIME initiative provides enhanced support and increased interaction to companies, with the goal of optimizing development plans and speeding regulatory evaluations to potentially bring in

Business Wire | September 23, 2020

Read More 'BLUE' Stories Here

BLUE Price Returns

1-mo -3.97%
3-mo -14.81%
6-mo -7.16%
1-year -37.59%
3-year -63.83%
5-year -38.72%
YTD -41.07%
2019 -11.54%
2018 -44.30%
2017 188.65%
2016 -3.92%
2015 -29.98%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7476 seconds.